Literature DB >> 11043526

Systemic nitroglycerin increases nNOS levels in rat trigeminal nucleus caudalis.

A Pardutz1, I Krizbai, S Multon, L Vecsei, J Schoenen.   

Abstract

Systemic administration of nitroglycerin, a nitric oxide donor, triggers in migraineurs a delayed attack of unknown mechanisms. Subcutaneous nitroglycerin (10 mg/kg) produced a significant increase of nitric oxide synthase (NOS)- and c-fos-immunoreactive neurons in the cervical part of trigeminal nucleus caudalis in rats after 4 h. This effect was not observed in the thoracic dorsal horn. Similar increase of NOS and c-fos was obtained in the brain stem after a somatic nociceptive stimulus, i.e. on the side of the formalin injection in the lip. Nitric oxide is thus able to increase NOS availability in second order nociceptive trigeminal neurons, which may be relevant for central sensitization and the understanding of its effect in migraine.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11043526     DOI: 10.1097/00001756-200009280-00008

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  23 in total

Review 1.  Headache-type adverse effects of NO donors: vasodilation and beyond.

Authors:  G Bagdy; P Riba; V Kecskeméti; D Chase; G Juhász
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

2.  Sodium MRI in a rat migraine model and a NEURON simulation study support a role for sodium in migraine.

Authors:  Michael G Harrington; Eduard Y Chekmenev; Victor Schepkin; Alfred N Fonteh; Xianghong Arakaki
Journal:  Cephalalgia       Date:  2011-08-04       Impact factor: 6.292

Review 3.  Where does a migraine attack originate? In the brainstem.

Authors:  J Tajti; D Szok; Á Párdutz; B Tuka; A Csáti; A Kuris; J Toldi; L Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2012-03-18       Impact factor: 3.575

4.  Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers.

Authors:  Milena De Felice; Michael H Ossipov; Ruizhong Wang; Gregory Dussor; Josephine Lai; Ian D Meng; Juliana Chichorro; John S Andrews; Suman Rakhit; Shawn Maddaford; David Dodick; Frank Porreca
Journal:  Brain       Date:  2010-07-13       Impact factor: 13.501

Review 5.  Emerging Treatment Targets for Migraine and Other Headaches.

Authors:  Zachariah Bertels; Amynah Amir Ali Pradhan
Journal:  Headache       Date:  2019-07       Impact factor: 5.887

Review 6.  Targeted Nitric Oxide Synthase Inhibitors for Migraine.

Authors:  Amynah A Pradhan; Zachariah Bertels; Simon Akerman
Journal:  Neurotherapeutics       Date:  2018-04       Impact factor: 7.620

Review 7.  Kynurenines and headache.

Authors:  Arpád Párdutz; Annamária Fejes; Zsuzsanna Bohár; Lilla Tar; József Toldi; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2011-06-04       Impact factor: 3.575

8.  Pre-treatment with new kynurenic acid amide dose-dependently prevents the nitroglycerine-induced neuronal activation and sensitization in cervical part of trigemino-cervical complex.

Authors:  Annamária Fejes-Szabó; Zsuzsanna Bohár; Enikő Vámos; Gábor Nagy-Grócz; Lilla Tar; Gábor Veres; Dénes Zádori; Márton Szentirmai; János Tajti; István Szatmári; Ferenc Fülöp; József Toldi; Árpád Párdutz; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2014-01-03       Impact factor: 3.575

9.  A comparative assessment of two kynurenic acid analogs in the formalin model of trigeminal activation: a behavioral, immunohistochemical and pharmacokinetic study.

Authors:  Gábor Veres; Annamária Fejes-Szabó; Dénes Zádori; Gábor Nagy-Grócz; Anna M László; Attila Bajtai; István Mándity; Márton Szentirmai; Zsuzsanna Bohár; Klaudia Laborc; István Szatmári; Ferenc Fülöp; László Vécsei; Árpád Párdutz
Journal:  J Neural Transm (Vienna)       Date:  2016-09-14       Impact factor: 3.575

Review 10.  Animal migraine models for drug development: status and future perspectives.

Authors:  Inger Jansen-Olesen; Peer Tfelt-Hansen; Jes Olesen
Journal:  CNS Drugs       Date:  2013-12       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.